The CRC for Cell Therapy Manufacturing, through CTM@CRC Ltd., will facilitate the cost-effective manufacture and rapid translation of cell therapies into clinical practice. With a total of $59M in cash and in-kind resources, including a $20M grant from the Australian Government, the CRC will provide new treatments and develop new materials-based manufacturing technologies for the treatment of conditions such as diabetes, chronic wounds, cardiovascular disease, and immune-mediated diseases such as graft versus host disease. Headquartered at UniSA’s Mawson Lakes campus, the CRC brings together the spectrum of skills and facilities required to turn a promising cell into a viable cell therapy. The CRC’s national and international partners include research providers, manufacturers, hospitals and charities. Underpinning this partnership is a newly established cGMP manufacturing facility, designed to deliver cell-based therapeutics for the CRC’s first-in-man clinical trials.